

TRUMENBA®

non-live (recombinant)
meningococcal group B vaccine

MenB-fHBP

10 years to 25 years

DIN 02468751



SUPPLIED:

prefilled syringe;
needle not supplied



PREPARATION:

ready-to-use;
DO NOT DILUTE



ADMINISTRATION:

IM injection



**APPROPRIATE
USE:**

- Not publicly funded in SK
- See QR code for recommendations for use.
- **Off-label Use:** may be considered for ≥ 26 years*



CIG



**BEYOND-USE
EXPIRY
DATE/TIME:**

- Check date on label (expiry date)
- 2°C and 8°C: use vaccine until expiry date.



HANDLING:

- Store horizontally to minimize re-dispersion time.
- **SHAKE VIGOROUSLY** before administration to re-suspend.



APPEARANCE:

- Homogeneous white suspension
- NO particulate matter/discoloration



DOSE:

- 0.5 mL



SERIES/SCHEDULE:

- **PRIMARY SERIES:**
 - Dosing schedule may depend on the risk of exposure and individual susceptibility to meningococcal serogroup B disease. See QR code for details.
 - 2-dose: 0, 6 months or 3-dose: 0, 4 weeks, 3rd dose to be given ≥ 4 months after 2nd dose (and at least 6 months after dose one).
- **BOOSTER:** May be considered for individuals at continued risk of invasive meningococcal disease. See PM for details.

* as per the CIG

REFERENCES:

- TRUMENBA® product monograph
- Canadian Immunization Guide: Meningococcal vaccines
- CATMAT Statement on Meningococcal Disease and the International Traveller

Financial contribution:



Public Health
Agency of Canada

Agence de la santé
publique du Canada

21 JUN 2024

©2024 medSask // Townes & Park Designs